| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.7M | -32.1% | -27.4% |
| SG&A Expense | $1.8M | +21.5% | +60.7% |
| Operating Income | -$3.5M | +11.7% | -1.9% |
| Net Income | -$3.4M | +12.6% | -1.5% |
| EPS (Basic) | -$0.07 | +72.0% | +93.2% |
| EPS (Diluted) | -$0.07 | +72.0% | +93.2% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $6.3M | -9.1% | +118.2% |
| Current Assets | $6.6M | -7.9% | +36.1% |
| Total Assets | $7.6M | -7.3% | +53.5% |
| Current Liabilities | $1.8M | -15.6% | +43.6% |
| Total Liabilities | $1.8M | -15.6% | +43.4% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.5M | — | — |
| Investing Cash Flow | -$3K | — | — |
| Financing Cash Flow | $13.6M | — | — |
| $5.8M |
| -4.5% |
| +56.8% |